EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

Zahi Mitri, Tina Constantine, Ruth O'Regan

Chemotherapy Research and Practice · 20.12.2012 · 2012 · 1-7

DOI: 10.1155/2012/743193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy Research and Practice, erschienen am 20.12.2012. Verfasst von Zahi Mitri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Emory University, Atlanta, GA 30322, USA. Die Arbeit wurde bisher 208-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20–30% of breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. Trastuzumab is a HER2 receptor blocker that has become the standard of care for the treatment of HER2 positive breast cancer. The effectiveness of Trastuzumab has been well validated in research as well as in clinical practice. The addition of Trastuzumab to standard of care chemotherapy in clinical trials has been shown to improve outcomes for early stage as well as metastatic HER2 positive breast cancer. The most clinically significant side effect of Trastuzumab is the risk of cardiac myocyte injury, leading to the development of congestive heart failure. The emergence of patterns of resistance to Trastuzumab has led to the discovery of new monoclonal antibodies and other targeted agents aimed at overcoming Trastuzumab resistance and improving survival in patients diagnosed with HER2 positive breast cancers.

Autor:innen und Institutionen

  • Department of Internal Medicine, Emory University, Atlanta, GA 30322, USA.

Zitieren

APA

Mitri, Z., Constantine, T., & O'Regan, R. (2012). The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemotherapy Research and Practice, 2012, 1-7. https://doi.org/10.1155/2012/743193

Vancouver

Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemotherapy Research and Practice. 2012;2012:1-7. doi:10.1155/2012/743193

BibTeX
@article{Mitri2012,
  author = {Mitri, Zahi and Constantine, Tina and O'Regan, Ruth},
  title = {The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy},
  journal = {Chemotherapy Research and Practice},
  year = {2012},
  volume = {2012},
  pages = {1--7},
  doi = {10.1155/2012/743193}
}
Kostenlos starten →